Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07303907 · ClinicalTrials.gov registry record · Phase 2
A Phase 2A Trial of MM402 for Autism Spectrum Disorder
A Phase 2 study of Autism Spectrum Disorder and ASD, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07303907: Recruiting Phase 2 study of Autism Spectrum Disorder and ASD, sponsored by Definium Therapeutics US.
NCT07303907 is a Phase 2 study of Autism Spectrum Disorder and ASD that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 20 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07303907, a Phase 2 study of Autism Spectrum Disorder and ASD, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder
Primary Outcome
The NRS is an 11-point PRO scale used to measure the severity or intensity of effects from 0 (no effect) to 10 (high severity or intensity of effect). It consists of various items related to both positive and negative effects in the autism patient population.
Conditions Studied
Interventions
- DRUG MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Study Locations (1)
New York
- Spectrum Neuroscience and Treatment Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT07303907 shows while recruiting
NCT07303907 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) is the first listed.
NCT07303907 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07303907 about?
NCT07303907 is a clinical study titled "A Phase 2A Trial of MM402 for Autism Spectrum Disorder". A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder
What is the current status of trial NCT07303907?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-12-03. Estimated completion is 2027-08.
What conditions does trial NCT07303907 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, ASD.
What interventions are being tested in trial NCT07303907?
The interventions under investigation include: MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) (DRUG).
Who is sponsoring clinical trial NCT07303907?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07303907 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07303907's enrollment target sits among peer trials
20 200th of 224 higher than 23 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI